Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

WuXi lands a lead role in Genomics England's big project

Chinese CRO WuXi PharmaTech is on board to help Genomics England pore over samples in its massive project to sequence the genomes of 100,000 Britons.

Fast-growing Charles River trades $36M for a drug discovery outfit

Charles River Laboratories, on the heels of some M&A-driven revenue growth, acquired another early-stage research company, paying $36 million for a German provider of drug discovery services.

Parexel touts its IT-enabled R&D services amid company shakeup

Parexel International, in the midst of sweeping cost cuts, said it has further integrated technology into its drug development services, creating a data-informed process designed to speed up timelines and save money.

PRA expands in Singapore with eyes on Asian growth

PRA Health Sciences is moving into a bigger space in Singapore, consolidating its operations there and looking to boost its share of the growing market for clinical research in Asia.

Quintiles lends its data-crunching know-how to Apple's ResearchKit

Quintiles has contributed some open-source code to improve Apple's ResearchKit project, a platform designed to help physicians and scientists gather medical data from millions of patients.

PPD deepens its Japanese focus with new joint venture leadership

PPD hired a general manager to help grow its Japan-focused joint venture with Shin Nippon Biomedical Laboratories, snagging a Parexel International veteran as it works to expand its presence in a growing market for clinical development services.

WuXi and Lilly pair up to develop a cardio drug in China

Eli Lilly is partnering with CRO WuXi PharmaTech to develop a cholesterol-lowering pill in China, relying on local expertise in hopes of tapping a growing market.

CRO BioDuro merges with Formex after a private equity takeout

BioDuro, once a division of PDD, has merged with contract manufacturer Formex, expanding its production capabilities in the U.S. while maintaining its research presence in China.

Quintiles founder stepping down as chairman after 33 years

Quintiles founder Dennis Gillings is set to vacate his chairmanship at the end of 2015, ending a 33-year tenure at the top that saw the North Carolina company grow into the world's biggest CRO.

Evotec posts 50% growth with a big year in sight

German contract researcher Evotec grew its revenue by 50% in the first 9 months of 2015, executing its hybrid model and expanding its list of Big Pharma partners.